This Hepagam B market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Market growth during the historic period can be attributed to a heightened focus on preventive healthcare, an increase in clinical trials, growth in liver transplantation procedures, a rise in the incidence of chronic illnesses, and growing awareness of co-infections.
The projected growth for the forecast period is driven by increased investments in research and development, expanding organ donation programs, rising government initiatives, a growing rate of hepatitis B infections, and increasing healthcare expenditure. Key trends in the forecast period include technological advancements, the adoption of combination vaccines, the integration of digital health tools, mobile health applications, and digital health platforms.
The rising prevalence of hepatitis B is expected to drive the growth of the hepagam B market. Hepatitis B infections, caused by the hepatitis B virus (HBV), can lead to chronic disease, cirrhosis, or liver cancer. The increase in hepatitis B cases is largely due to insufficient vaccination coverage, higher transmission rates in high-risk populations, and a lack of awareness about preventive measures. HepaGam B helps prevent hepatitis B infection by providing passive immunity to individuals exposed to the virus. For example, according to the World Health Organization, an estimated 254 million people globally were living with chronic hepatitis B in 2022, with 1.2 million new cases reported annually. The disease caused approximately 1.1 million deaths, primarily due to cirrhosis and liver cancer. Thus, the growing prevalence of hepatitis B is expected to propel the hepagam B market.
The increasing healthcare expenditure is also anticipated to accelerate the growth of the hepagam B market. Factors such as an aging population, rising chronic disease prevalence, medical advancements, and increased demand for quality healthcare are driving this rise in spending. Higher healthcare spending supports the HepaGam B market by enabling more investment in preventive treatments, improving access to immunoglobulin therapies, and enhancing the management of hepatitis B-related complications. For example, in October 2022, the Office for National Statistics reported that healthcare expenditure in the UK reached approximately $367.9 billion (£283 billion) in 2022, marking a 0.7% increase from 2021. Non-government healthcare spending rose by 9.5% in nominal terms and 3.9% in real terms. As a result, the growing healthcare expenditure will contribute to the market expansion of hepagam B.
A key trend in the hepagam B market is the expansion of plasma collection centers to strengthen market positioning. Plasma collection involves extracting plasma from donors' blood, which is used for various treatments, including the production of immunoglobulins and clotting factor therapies. For instance, in September 2024, Kamada Limited, an Israel-based biopharmaceutical company, opened a new plasma collection center in Houston, Texas. This 12,000-square-foot facility is expected to support over 50 donor beds and achieve an annual collection capacity of approximately 50,000 liters. The center will focus on collecting both normal and specialty plasma, generating an estimated $8 million to $10 million in annual revenue at full capacity. This expansion is part of Kamada's strategy to become a leading player in the global specialty plasma-derived market.
Major companies operating in the hepagam B market are Kamada Ltd., Kibiopharma Inc., and Emergent BioSolutions Inc.
North America was the largest region in the hepagam B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepagam B report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepagam B market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
HepaGam B is a human hepatitis B immune globulin used to prevent hepatitis B infection in individuals exposed to the virus, such as healthcare workers or newborns of infected mothers. It provides passive immunity by delivering antibodies against hepatitis B surface antigens. Typically administered via injection, it is an important part of post-exposure prophylaxis.
The main types of hepaGam B products include immunoglobulin preparations, vaccines, and antiviral therapies. Immunoglobulin preparations are plasma-derived products that contain antibodies offering passive immunity against specific infections. HepaGam B is used for post-exposure prophylaxis and chronic hepatitis B treatment, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The hepagam B market research report is one of a series of new reports that provides hepagam B market statistics, including hepagam B industry global market size, regional shares, competitors with a hepagam B market share, detailed hepagam B market segments, market trends and opportunities, and any further data you may need to thrive in the hepagam B industry. This hepagam B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepagam B market consists of sales of hepatitis B vaccines, intravenous immunoglobulin, subcutaneous immunoglobulin, and hepatitis A immunoglobulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Market growth during the historic period can be attributed to a heightened focus on preventive healthcare, an increase in clinical trials, growth in liver transplantation procedures, a rise in the incidence of chronic illnesses, and growing awareness of co-infections.
The projected growth for the forecast period is driven by increased investments in research and development, expanding organ donation programs, rising government initiatives, a growing rate of hepatitis B infections, and increasing healthcare expenditure. Key trends in the forecast period include technological advancements, the adoption of combination vaccines, the integration of digital health tools, mobile health applications, and digital health platforms.
The rising prevalence of hepatitis B is expected to drive the growth of the hepagam B market. Hepatitis B infections, caused by the hepatitis B virus (HBV), can lead to chronic disease, cirrhosis, or liver cancer. The increase in hepatitis B cases is largely due to insufficient vaccination coverage, higher transmission rates in high-risk populations, and a lack of awareness about preventive measures. HepaGam B helps prevent hepatitis B infection by providing passive immunity to individuals exposed to the virus. For example, according to the World Health Organization, an estimated 254 million people globally were living with chronic hepatitis B in 2022, with 1.2 million new cases reported annually. The disease caused approximately 1.1 million deaths, primarily due to cirrhosis and liver cancer. Thus, the growing prevalence of hepatitis B is expected to propel the hepagam B market.
The increasing healthcare expenditure is also anticipated to accelerate the growth of the hepagam B market. Factors such as an aging population, rising chronic disease prevalence, medical advancements, and increased demand for quality healthcare are driving this rise in spending. Higher healthcare spending supports the HepaGam B market by enabling more investment in preventive treatments, improving access to immunoglobulin therapies, and enhancing the management of hepatitis B-related complications. For example, in October 2022, the Office for National Statistics reported that healthcare expenditure in the UK reached approximately $367.9 billion (£283 billion) in 2022, marking a 0.7% increase from 2021. Non-government healthcare spending rose by 9.5% in nominal terms and 3.9% in real terms. As a result, the growing healthcare expenditure will contribute to the market expansion of hepagam B.
A key trend in the hepagam B market is the expansion of plasma collection centers to strengthen market positioning. Plasma collection involves extracting plasma from donors' blood, which is used for various treatments, including the production of immunoglobulins and clotting factor therapies. For instance, in September 2024, Kamada Limited, an Israel-based biopharmaceutical company, opened a new plasma collection center in Houston, Texas. This 12,000-square-foot facility is expected to support over 50 donor beds and achieve an annual collection capacity of approximately 50,000 liters. The center will focus on collecting both normal and specialty plasma, generating an estimated $8 million to $10 million in annual revenue at full capacity. This expansion is part of Kamada's strategy to become a leading player in the global specialty plasma-derived market.
Major companies operating in the hepagam B market are Kamada Ltd., Kibiopharma Inc., and Emergent BioSolutions Inc.
North America was the largest region in the hepagam B market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hepagam B report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the hepagam B market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
HepaGam B is a human hepatitis B immune globulin used to prevent hepatitis B infection in individuals exposed to the virus, such as healthcare workers or newborns of infected mothers. It provides passive immunity by delivering antibodies against hepatitis B surface antigens. Typically administered via injection, it is an important part of post-exposure prophylaxis.
The main types of hepaGam B products include immunoglobulin preparations, vaccines, and antiviral therapies. Immunoglobulin preparations are plasma-derived products that contain antibodies offering passive immunity against specific infections. HepaGam B is used for post-exposure prophylaxis and chronic hepatitis B treatment, and is distributed through hospital pharmacies, retail pharmacies, and online pharmacies.
The hepagam B market research report is one of a series of new reports that provides hepagam B market statistics, including hepagam B industry global market size, regional shares, competitors with a hepagam B market share, detailed hepagam B market segments, market trends and opportunities, and any further data you may need to thrive in the hepagam B industry. This hepagam B market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The hepagam B market consists of sales of hepatitis B vaccines, intravenous immunoglobulin, subcutaneous immunoglobulin, and hepatitis A immunoglobulin. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 3-5 business days.
Table of Contents
1. Executive Summary2. Hepagam B Market Characteristics4. Hepagam B Market Trends and Strategies5. Hepagam B Market -Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market7. Global Hepagam B Pricing Analysis & Forecasts30. Global Hepagam B Market Competitive Benchmarking and Dashboard31. Key Mergers and Acquisitions in the Hepagam B Market32. Recent Developments in the Hepagam B Market
3. Hepagam B Market Biologic Drug Characteristics
6. Global Hepagam B Growth Analysis and Strategic Analysis Framework
8. Hepagam B Market Segmentation
9. Global Hepagam B Epidemiology of Clinical Indications
10. Hepagam B Market Regional and Country Analysis
11. Asia-Pacific Hepagam B Market
12. China Hepagam B Market
13. India Hepagam B Market
14. Japan Hepagam B Market
15. Australia Hepagam B Market
16. South Korea Hepagam B Market
17. Western Europe Hepagam B Market
18. UK Hepagam B Market
19. Germany Hepagam B Market
20. France Hepagam B Market
21. Eastern Europe Hepagam B Market
22. North America Hepagam B Market
23. USA Hepagam B Market
24. Canada Hepagam B Market
25. South America Hepagam B Market
26. Middle East Hepagam B Market
27. Africa Hepagam B Market
28. Hepagam B Market Competitive Landscape and Company Profiles
29. Global Hepagam B Market Pipeline Analysis
33. Hepagam B Market High Potential Countries, Segments and Strategies
34. Appendix
Executive Summary
Hepagam B Global Market Report 2025 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on hepagam b market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hepagam b? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The hepagam b market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
Markets Covered:
1) by Product Type: Immunoglobulin Preparations; Vaccines; Antiviral Therapies2) by Indication: Post-Exposure Prophylaxis; Chronic Hepatitis B Treatment
3) by Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
Key Companies Mentioned: Kamada Ltd.; Kibiopharma Inc.; Emergent BioSolutions Inc.
Countries: Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
- Kamada Ltd.
- Kibiopharma Inc.
- Emergent BioSolutions Inc.
